288 related articles for article (PubMed ID: 19362101)
1. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity.
Cosgrove BD; King BM; Hasan MA; Alexopoulos LG; Farazi PA; Hendriks BS; Griffith LG; Sorger PK; Tidor B; Xu JJ; Lauffenburger DA
Toxicol Appl Pharmacol; 2009 Jun; 237(3):317-30. PubMed ID: 19362101
[TBL] [Abstract][Full Text] [Related]
2. A multipathway phosphoproteomic signaling network model of idiosyncratic drug- and inflammatory cytokine-induced toxicity in human hepatocytes.
Cosgrove BD; Alexopoulos LG; Saez-Rodriguez J; Griffith LG; Lauffenburger DA
Annu Int Conf IEEE Eng Med Biol Soc; 2009; 2009():5452-5. PubMed ID: 19964679
[TBL] [Abstract][Full Text] [Related]
3. Implication of hepatic transporters (MDR1 and MRP2) in inflammation-associated idiosyncratic drug-induced hepatotoxicity investigated by microvolume cytometry.
Saab L; Peluso J; Muller CD; Ubeaud-Sequier G
Cytometry A; 2013 Apr; 83(4):403-8. PubMed ID: 23401306
[TBL] [Abstract][Full Text] [Related]
4. Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation.
Cosgrove BD; Alexopoulos LG; Hang TC; Hendriks BS; Sorger PK; Griffith LG; Lauffenburger DA
Mol Biosyst; 2010 Jul; 6(7):1195-206. PubMed ID: 20361094
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of in vitro combination assays of mitochondrial dysfunction and apoptosis for the estimation of potential risk of idiosyncratic drug induced liver injury.
Goda K; Takahashi T; Kobayashi A; Shoda T; Kuno H; Sugai S
J Toxicol Sci; 2016; 41(5):605-15. PubMed ID: 27665770
[TBL] [Abstract][Full Text] [Related]
6. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
Utkarsh D; Loretz C; Li AP
Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
[TBL] [Abstract][Full Text] [Related]
7. Omics-based identification of the combined effects of idiosyncratic drugs and inflammatory cytokines on the development of drug-induced liver injury.
Jiang J; Mathijs K; Timmermans L; Claessen SM; Hecka A; Weusten J; Peters R; van Delft JH; Kleinjans JCS; Jennen DGJ; de Kok TM
Toxicol Appl Pharmacol; 2017 Oct; 332():100-108. PubMed ID: 28733206
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of hepatocellular apoptosis induced by trovafloxacin-tumor necrosis factor-alpha interaction.
Beggs KM; Fullerton AM; Miyakawa K; Ganey PE; Roth RA
Toxicol Sci; 2014 Jan; 137(1):91-101. PubMed ID: 24097668
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Cytotoxicity from Drugs and Cytokines In Vitro as an Approach to Classify Drugs According to Their Potential to Cause Idiosyncratic Hepatotoxicity: A Proof-of-Concept Study.
Maiuri AR; Wassink B; Turkus JD; Breier AB; Lansdell T; Kaur G; Hession SL; Ganey PE; Roth RA
J Pharmacol Exp Ther; 2017 Sep; 362(3):459-473. PubMed ID: 28687704
[TBL] [Abstract][Full Text] [Related]
10. Sulindac metabolism and synergy with tumor necrosis factor-alpha in a drug-inflammation interaction model of idiosyncratic liver injury.
Zou W; Beggs KM; Sparkenbaugh EM; Jones AD; Younis HS; Roth RA; Ganey PE
J Pharmacol Exp Ther; 2009 Oct; 331(1):114-21. PubMed ID: 19638570
[TBL] [Abstract][Full Text] [Related]
11. The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury.
Tukov FF; Luyendyk JP; Ganey PE; Roth RA
Toxicol Sci; 2007 Nov; 100(1):267-80. PubMed ID: 17698507
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles.
Zhang J; Doshi U; Suzuki A; Chang CW; Borlak J; Li AP; Tong W
Chem Biol Interact; 2016 Aug; 255():3-11. PubMed ID: 26581450
[TBL] [Abstract][Full Text] [Related]
13. Co-culture of Hepatocytes and Kupffer Cells as an In Vitro Model of Inflammation and Drug-Induced Hepatotoxicity.
Rose KA; Holman NS; Green AM; Andersen ME; LeCluyse EL
J Pharm Sci; 2016 Feb; 105(2):950-964. PubMed ID: 26869439
[TBL] [Abstract][Full Text] [Related]
14. Prediction of drug-induced immune-mediated hepatotoxicity using hepatocyte-like cells derived from human embryonic stem cells.
Kim DE; Jang MJ; Kim YR; Lee JY; Cho EB; Kim E; Kim Y; Kim MY; Jeong WI; Kim S; Han YM; Lee SH
Toxicology; 2017 Jul; 387():1-9. PubMed ID: 28645575
[TBL] [Abstract][Full Text] [Related]
15. Cellular imaging predictions of clinical drug-induced liver injury.
Xu JJ; Henstock PV; Dunn MC; Smith AR; Chabot JR; de Graaf D
Toxicol Sci; 2008 Sep; 105(1):97-105. PubMed ID: 18524759
[TBL] [Abstract][Full Text] [Related]
16. Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha.
Shaw PJ; Hopfensperger MJ; Ganey PE; Roth RA
Toxicol Sci; 2007 Nov; 100(1):259-66. PubMed ID: 17709330
[TBL] [Abstract][Full Text] [Related]
17. [The idiosyncratic hepatotoxicity of Polygonum multiflorum based on endotoxin model].
Li CY; Li XF; Tu C; Li N; Ma ZJ; Pang JY; Jia GL; Cui HR; You Y; Song HB; Du XX; Zhao YL; Wang JB; Xiao XH
Yao Xue Xue Bao; 2015 Jan; 50(1):28-33. PubMed ID: 25924471
[TBL] [Abstract][Full Text] [Related]
18. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology.
Prandota J
Am J Ther; 2005; 12(3):254-61. PubMed ID: 15891270
[TBL] [Abstract][Full Text] [Related]
19. Role of metabolism in drug-induced idiosyncratic hepatotoxicity.
Walgren JL; Mitchell MD; Thompson DC
Crit Rev Toxicol; 2005; 35(4):325-61. PubMed ID: 15989140
[TBL] [Abstract][Full Text] [Related]
20. The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro.
Giustarini G; Huppelschoten S; Barra M; Oppelt A; Wagenaar L; Weaver RJ; Bol-Schoenmakers M; Smit JJ; van de Water B; Klingmüller U; Pieters RHH
Toxicol Appl Pharmacol; 2020 Mar; 391():114915. PubMed ID: 32035082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
